Stock Track | Intellia Therapeutics Soars 18.11% on Promising Drug Data, Bullish Analyst Rating

Stock Track11-18

Shares of Intellia Therapeutics (NTLA) soared 18.11% during Monday's trading session, outperforming the broader market on optimism over the company's promising drug candidate.

The rally was fueled by a bullish analyst report from JonesTrading on November 13th, which reiterated a Buy rating on NTLA stock. Analyst Debanjana Chatterjee cited promising efficacy and safety data for the company's Nex-Z treatment as the basis for the positive outlook.

Intellia is a leading gene editing company focused on developing curative therapeutics using CRISPR technology. Positive data readouts and analyst support have renewed investor confidence in the company's pipeline and future growth prospects.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1126356414?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-18 16:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1126356414","market":"us","top_or_hot":-1,"title":"Stock Track | Intellia Therapeutics Soars 18.11% on Promising Drug Data, Bullish Analyst Rating","media":"Stock Track","content":"<p>Shares of Intellia Therapeutics (NTLA) soared 18.11% during Monday's trading session, outperforming the broader market on optimism over the company's promising drug candidate.</p>\n\n<p>The rally was fueled by a bullish analyst report from JonesTrading on November 13th, which reiterated a Buy rating on NTLA stock. Analyst Debanjana Chatterjee cited promising efficacy and safety data for the company's Nex-Z treatment as the basis for the positive outlook.</p>\n\n<p>Intellia is a leading gene editing company focused on developing curative therapeutics using CRISPR technology. Positive data readouts and analyst support have renewed investor confidence in the company's pipeline and future growth prospects.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Intellia Therapeutics Soars 18.11% on Promising Drug Data, Bullish Analyst Rating</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Intellia Therapeutics Soars 18.11% on Promising Drug Data, Bullish Analyst Rating\n</h2>\n\n<h4 class=\"meta\">\n\n2024-11-18 16:38 北京时间&nbsp;&nbsp;&nbsp;<strong>Stock Track</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of Intellia Therapeutics (NTLA) soared 18.11% during Monday's trading session, outperforming the broader market on optimism over the company's promising drug candidate.\nThe rally was fueled by ...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NTLA","symbol_name":"Intellia Therapeutics Inc","start_time":0,"source_url":"","article_id":"1126356414","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1126356414","pubTimestamp":1731919100,"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Intellia Therapeutics  soared 18.11% during Monday's trading session, outperforming the broader market on optimism over the company's promising drug candidate.The rally was fueled by a bullish analyst report from JonesTrading on November 13th, which reiterated a Buy rating on NTLA stock. Analyst Debanjana Chatterjee cited promising efficacy and safety data for the company's Nex-Z treatment as the basis for the positive outlook.Intellia is a leading gene editing company focused on devel","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NTLA":"Intellia Therapeutics Inc"},"translate_title":"股票跟踪Intellia Therapeutics因药物数据乐观和分析师评级看涨而飙升18.11%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NTLA":1},"content_text":"Shares of Intellia Therapeutics (NTLA) soared 18.11% during Monday's trading session, outperforming the broader market on optimism over the company's promising drug candidate.\nThe rally was fueled by a bullish analyst report from JonesTrading on November 13th, which reiterated a Buy rating on NTLA stock. Analyst Debanjana Chatterjee cited promising efficacy and safety data for the company's Nex-Z treatment as the basis for the positive outlook.\nIntellia is a leading gene editing company focused on developing curative therapeutics using CRISPR technology. Positive data readouts and analyst support have renewed investor confidence in the company's pipeline and future growth prospects.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1126356414"}